Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

HUTCHMED (China) Limited Sponsored ADR HCM

Healthcare  —  Drug Manufacturers Specialty & Generic
13.94 0.04 0.29% as of 25 Sep
Market cap
$2.4B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

HUTCHMED (China) Limited Sponsored ADR (HCM) Business Profile

Updated before January 2025

Company Overview

HUTCHMED (China) Limited Sponsored ADR (HCM) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Founded in 2000, the company is headquartered in Hong Kong, with significant operations in China and a growing presence in global markets, including the United States and Europe. HUTCHMED was established as a subsidiary of Hutchison Whampoa Limited, a multinational conglomerate, and has since evolved into an independent entity listed on the NASDAQ and the Hong Kong Stock Exchange. The company is led by an experienced management team, including CEO Christian Hogg, who has been instrumental in driving HUTCHMED’s growth and innovation.

Core Business Segments

HUTCHMED operates across three primary business segments:

1. Oncology/Immunology

This segment focuses on the development and commercialization of innovative therapies for cancer and immune-related diseases. Key products include:

  • Elunate® (fruquintinib): An oral VEGFR inhibitor approved in China for the treatment of metastatic colorectal cancer.
  • Surufatinib: A novel oral inhibitor targeting VEGFR, FGFR, and CSF-1R, approved in China for neuroendocrine tumors.
  • Savolitinib: A selective MET inhibitor developed in collaboration with AstraZeneca, targeting MET-driven cancers.

2. Innovation Platform

HUTCHMED’s Innovation Platform is dedicated to drug discovery and development. The company leverages its proprietary research capabilities to create a robust pipeline of drug candidates. This segment includes:

  • Early-stage clinical trials for novel therapies.
  • Partnerships with global pharmaceutical companies for co-development and commercialization.

3. China Healthcare Business

This segment encompasses the manufacturing, marketing, and distribution of prescription and over-the-counter drugs in China. Key offerings include:

  • Traditional Chinese Medicine (TCM) products.
  • Generic pharmaceuticals for common ailments.

Business Model

HUTCHMED’s business model is built on a vertically integrated approach that combines drug discovery, clinical development, manufacturing, and commercialization. The company generates revenue through:

  • Product Sales: Revenue from the sale of approved drugs like Elunate® and Surufatinib.
  • Collaborations: Licensing agreements and partnerships with global pharmaceutical companies, such as AstraZeneca and Eli Lilly.
  • China Healthcare Business: Revenue from the sale of TCM and generic drugs in the Chinese market.

HUTCHMED invests heavily in research and development (R&D), allocating a significant portion of its revenue to advance its drug pipeline. The company also focuses on expanding its global footprint through strategic partnerships and regulatory approvals in international markets.

Strategic Direction

HUTCHMED aims to become a global leader in oncology and immunology by pursuing the following strategic initiatives:

  • Pipeline Expansion: Accelerating the development of its robust pipeline, which includes over a dozen drug candidates in various stages of clinical trials.
  • Global Market Penetration: Securing regulatory approvals and launching products in key markets, including the United States, Europe, and Japan.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and supply chain operations.
  • New Product Categories: Exploring opportunities in adjacent therapeutic areas, such as autoimmune diseases and rare genetic disorders.

Competitive Landscape

HUTCHMED operates in a highly competitive biopharmaceutical industry, facing competition from both domestic and international players. Key competitors include:

  • BeiGene: A Chinese biopharmaceutical company specializing in oncology.
  • Innovent Biologics: Focused on developing and commercializing biologics for cancer and autoimmune diseases.
  • AstraZeneca: A global pharmaceutical company and HUTCHMED’s partner in the development of savolitinib.
  • Eli Lilly: Another global pharmaceutical giant collaborating with HUTCHMED on Elunate®.

Despite the competition, HUTCHMED differentiates itself through its strong R&D capabilities, innovative drug pipeline, and strategic partnerships.

Risk Factors

HUTCHMED faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for new drugs.
  • Market Dependence: Heavy reliance on the success of key products like Elunate® and Surufatinib.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials or manufacturing processes.
  • Competition: Intense competition from established players and emerging biotech companies.
  • Geopolitical Risks: Trade tensions and regulatory changes in key markets, such as the United States and China.

Recent Developments

HUTCHMED has made significant progress in recent years, including:

  • Regulatory Approvals: Obtaining FDA approval for fruquintinib in the United States for colorectal cancer.
  • Partnerships: Expanding collaborations with global pharmaceutical companies to co-develop and commercialize innovative therapies.
  • Clinical Trials: Advancing multiple drug candidates into late-stage clinical trials, including combination therapies for cancer.
  • Global Expansion: Establishing a presence in Europe and Japan to support future product launches.

Investment Considerations

Investors considering HUTCHMED should weigh the following factors:

Strengths:

  • Robust pipeline of innovative drug candidates.
  • Strong R&D capabilities and proprietary technology.
  • Strategic partnerships with global pharmaceutical companies.
  • Growing presence in international markets.

Risks:

  • Dependence on a few key products for revenue.
  • High R&D expenses impacting short-term profitability.
  • Regulatory and geopolitical risks in key markets.

Conclusion

HUTCHMED (China) Limited Sponsored ADR is well-positioned to capitalize on the growing demand for innovative cancer therapies and immunological treatments. With a strong pipeline, strategic partnerships, and a focus on global expansion, the company is poised for long-term growth. However, investors should carefully consider the risks associated with regulatory approvals, market competition, and geopolitical factors. Overall, HUTCHMED represents a compelling investment opportunity in the biopharmaceutical sector, driven by its commitment to innovation and patient-centric solutions.